Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial

What Was Tested

This randomized controlled trial paper looks at BNP (Nesiritide).

Who Took Part

The study group was 360 patients.

PubMed indexes the participants as middle-aged adults, older adults and people over 80, both men and women.

Enrollment occurred from September 2010 to March 2013 across 26 sites in North America.

Participants were randomized in an open, 1:1 allocation ratio to the dopamine or nesiritide strategy.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on BNP (Nesiritide), so expectations could not easily colour the readings.

Some patients received a placebo instead of BNP (Nesiritide), giving a reference point.

More than one site took part, so the patients came from several places.

Within each strategy, participants were randomized in a double-blind, 2:1 ratio to active treatment or placebo.

The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared with the pooled placebo group (n = 119).

What Was Measured

PubMed files the paper under topics including Acute Disease, Cystatin C, Diuretics, Dopamine, Glomerular Filtration Rate, Heart Failure and Kidney.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of BNP (Nesiritide) in 360 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (JAMA), a journal based in United States.

More context: the BNP (Nesiritide) compound page.